Journal
PEDIATRIC BLOOD & CANCER
Volume 62, Issue 8, Pages 1326-1336Publisher
WILEY
DOI: 10.1002/pbc.25513
Keywords
bispecific antibodies; chimeric antigen receptors; immunotherapy; pediatric oncology; T cells
Categories
Funding
- Enid A Haupt Endowed Chair
- Kids Walk for Kids with Cancer NYC
- Katie's Find a Cure Foundation
- Catie Hoch Foundation
- Robert Steel Foundation
Ask authors/readers for more resources
Cancer immunotherapy using antigen-specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging. Pediatr Blood Cancer 2015;62:1326-1336. (c) 2015 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available